
Efruxifermin reduces liver scarring in mid-stage trial, showing promising results for NASH treatment.


coremsg

Akero Therapeutics&#039; experimental drug for a type of fatty liver disease significantly reduced scarring after nearly two years in a mid-stage study, it said on Monday, as the...

Akero's Fatty Liver Disease Drug Lessens Scarring in Mid-stage Trial

akero-s-efruxifermin-reduces-liver-scarring-in-mid-stage-trial


Akero's Efruxifermin Reduces Liver Scarring in Mid-stage Trial
